Do Faecalibacterium prausnitzii and Butyrivibrio crossotus produce butyrate that supports intestinal energy metabolism and immune regulation?

The claim that Faecalibacterium prausnitzii and Butyrivibrio crossotus are butyrate-producing bacteria, and that their depletion reduces the microbial butyrate output necessary for colonic epithelial energy metabolism and mucosal immune regulation, is fully supported by established scientific evidence.

Microbial butyrate production and taxon depletion

• Butyrate synthesis pathways: Both Faecalibacterium prausnitzii and Butyrivibrio crossotus are validated butyrate-producing anaerobes. They utilize a highly conserved acetyl-CoA-to-butyryl-CoA core pathway. The terminal synthesis step is executed by the enzyme butyryl-CoA:acetate CoA-transferase, which couples butyrate generation with the consumption of exogenous acetate.
• Impact of depletion: F. prausnitzii is highly abundant, representing 5% to 15% of the total colonic microbiota in healthy adults. Quantitative clinical studies demonstrate a direct correlation between the depletion of these taxa and reduced luminal butyrate. For instance, dietary transitions to fiber-free regimens cause synchronized drops in F. prausnitzii counts and fecal butyrate levels, while inflammatory states like inflammatory bowel disease (IBD) reveal a joint depletion of F. prausnitzii and Butyrivibrio that matches a profound drop in butyryl-CoA:acetate CoA-transferase gene copy numbers.

Epithelial energy metabolism and mucosal immune regulation

• Epithelial energy metabolism: Healthy colonocytes rely on microbially derived butyrate to meet approximately 70% to 80% of their baseline energy demands. Mitochondria rapidly oxidize butyrate to acetyl-CoA to fuel the tricarboxylic acid (TCA) cycle and oxidative phosphorylation. When butyrate is depleted, colonocytes undergo an inefficient metabolic shift toward glycolysis, which fails to restore baseline adenosine triphosphate (ATP) levels, leaving the epithelial barrier fragile and prone to dysfunction.
• Immune regulation mechanisms: Butyrate acts as a critical signal for mucosal immune tolerance via two primary pathways:
  1. Histone deacetylase (HDAC) inhibition: Butyrate functions as a class I HDAC inhibitor. This inhibition leads to hyperacetylation of histone H3 at the Foxp3 promoter and conserved non-coding sequence regions, promoting Foxp3+ regulatory T cell (Treg) differentiation.
  2. GPCR signaling: Butyrate acts as a ligand for G-protein coupled receptors GPR43 and GPR109A. This signaling induces a tolerogenic phenotype in dendritic cells and macrophages, driving the production of interleukin-10 (IL-10) and retinoic acid to suppress mucosal inflammation.

Bottom line

Faecalibacterium prausnitzii and Butyrivibrio crossotus are essential components of the intestinal metabolic machinery; their depletion directly reduces luminal butyrate levels, depriving colonocytes of their primary energy source and compromising the epigenetic and receptor-mediated pathways that maintain mucosal immune tolerance.